Morphogen-IX Ltd.

Founded by UK life sciences venture capital firm Medicxi, Centessa Pharmaceuticals is headed up by industry heavyweights. Saurabh Saha, who was formerly Bristol Myers Squibb Company ’s head of R&D

Centessa Pharmaceuticals has launched with a first-of-its-kind model involving the merger of ten biotechs and $250m in series A backing. The new company was created through the merger of ten private

Despite uncertainty associated with the torturous discussions around the UK’s planned exit from the European Union, Cambridge Innovation Capital has secured an additional £150m ($196m) to finance the

Relay Therapeutics has raised $520m in venture capital since 2016, including a $400m Series C round announced on Dec. 20, without relaying a lot of information publicly about how it will translate it